Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Receivables data on record, last reported at $5.1 million in Q3 2025.

  • For Q3 2025, Receivables rose 36.8% year-over-year to $5.1 million; the TTM value through Sep 2025 reached $5.1 million, up 36.8%, while the annual FY2024 figure was $4.6 million, 4.72% down from the prior year.
  • Receivables reached $5.1 million in Q3 2025 per TNXP's latest filing, up from $4.2 million in the prior quarter.
  • Across five years, Receivables topped out at $9.2 million in Q4 2023 and bottomed at $2.3 million in Q3 2023.
  • Average Receivables over 3 years is $4.5 million, with a median of $4.0 million recorded in 2024.
  • The widest YoY moves for Receivables: up 62.24% in 2024, down 50.28% in 2024.
  • A 3-year view of Receivables shows it stood at $9.2 million in 2023, then tumbled by 50.28% to $4.6 million in 2024, then rose by 12.82% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $5.1 million in Q3 2025, $4.2 million in Q2 2025, and $3.5 million in Q1 2025.